title: Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada.
abstract: OBJECTIVE
  To evaluate the trends in abacavir (ABC) prescription among antiretroviral (ARV) medication-naive individuals following the presentation of the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) cohort study.
  
  
  METHODS
  We conducted a retrospective cohort study of ARV medication-naive individuals in the Canadian Observational Cohort (CANOC).
  
  
  RESULTS
  Between January 1, 2000, and February 28, 2010, a total of 7280 ARV medication-naive patients were included in CANOC. We observed a significant change in the proportion of new ABC prescriptions immediately following the release of DAD (-11%; 95% confidence interval [CI]: -20% to -2.4%) and in the months following the presentation of these data (-0.66% per month; 95% CI: -1.2% to -0.073%). A post-DAD presentation decrease in the odds of being prescribed ABC versus tenofovir (TDF) was observed (adjusted odds ratio, 0.72 per year, 95% CI: 0.54-0.97).
  
  
  CONCLUSIONS
  Presentation of the DAD was associated with a significant decrease in ABC use among ARV medication-naive, HIV-positive patients initiating therapy.
authors.affiliation: Department of Family and Community Medicine, St Michael's Hospital, Toronto, Ontario, Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: Antoniou
authors.forename: Jennifer
authors.initials: J
authors.lastname: Gillis
authors.forename: Mona R
authors.initials: MR
authors.lastname: Loutfy
authors.forename: Curtis
authors.initials: C
authors.lastname: Cooper
authors.forename: Robert S
authors.initials: RS
authors.lastname: Hogg
authors.forename: Marina B
authors.initials: MB
authors.lastname: Klein
authors.forename: Nima
authors.initials: N
authors.lastname: Machouf
authors.forename: Julio S G
authors.initials: JS
authors.lastname: Montaner
authors.forename: Sean B
authors.initials: SB
authors.lastname: Rourke
authors.forename: Chris
authors.initials: C
authors.lastname: Tsoukas
authors.forename: Janet M
authors.initials: JM
authors.lastname: Raboud
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002170:Canada; D015331:Cohort Studies; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D033181:Information Dissemination; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D010818:Practice Patterns, Physicians' / Q000639:trends*; D012189:Retrospective Studies; D012307:Risk Factors; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D000099227:Abacavir
keywords: HIV; abacavir; drug utilization; pharmacoepidemiology